Zimmer Biomet Holdings, Inc.
ZBHHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeZimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The $15.93B market capitalization puts ZBH squarely in large-cap range for its industry. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T.
Market Cap
$15.93B
Beta
0.47
P/E (TTM)
21.33
P/E (Fwd)
9.15
EPS (TTM)
$3.86
EPS (Fwd)
$9.01
ROE
6.1%
ROA
4.1%
Cash
$478.5M
Total Debt
$7.59B
Free CF
$1.04B
52W Change
-9.6%
Annual Financials
Cash vs Debt
On the balance sheet, ZBH has $478.5M in cash with $7.59B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Free cash flow comes in at $1.04B, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 6.1% points to modest capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 4.1% is on the lower side, which is common in asset-heavy industries. Revenue has been uneven over recent years, ranging from $6.94B to $8.23B.
ZBH's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. Debt significantly exceeds cash reserves, which means the company's financial flexibility could be constrained during economic downturns. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing ZBH.